Acknowledgements We thank Umut Erhan, Azadeh Houshman-regaard and Anders Strathe of Novo Nordisk A/S (Denmark) and Zu Ning of Novo Nordisk China A/S (China) for their contributions to the manuscript
Healthcare providers may sometimes recommend: alternative GLP-1 medications adjusting dose schedules temporary medication substitutions These decisions should always be made with guidance from a healthcare professional
As a GLP-1 receptor agonist, semaglutide mimics GLP-1, the hormone that helps regulate your appetite
Patients who struggle with injections or have injection anxiety may achieve better long-term outcomes with oral formulations, despite needing higher doses and stricter administration protocols
If a person has gigantism or acromegaly, high blood sugar levels do not affect GH production as the pituitary gland does not respond correctly
(Breast progression to stage IV 10% vs 20% versus DPP-4 inhibitor.) American Society of Clinical Oncology
